clinical trials aiming to reduce the toxicity of novel agents in aml
Published 1 year ago • 199 plays • Length 6:41Download video MP4
Download video MP3
Similar videos
-
2:36
intensive induction chemotherapy vs hma/ven in npm1-mutant aml: a retrospective study
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:40
the role of menin inhibitors in the treatment of aml
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
2:34
the evolution of the aml treatment paradigm
-
3:40
how the aml treatment landscape has evolved with the use of novel combination therapies
-
1:06:04
itp: novel treatments
-
5:09
what do you see as the future of aml treatments? #aml
-
3:51
novel agents in mzl: btkis, pi3k inhibitors, and immunotherapeutics
-
1:29
the current landscape of maintenace therapy in aml and areas for future exploration
-
1:07
an insight into the pathogenesis of aml
-
1:55
cardiotoxicity of cpx-351 vs 7 3 chemotherapy in patients with untreated high-risk aml
-
2:38
flt3 inhibitors: revolutionizing the management of aml
-
3:37
the future of aml treatment
-
1:55
diagnosing and treating aml: the role of mutational profiling
-
4:31
limitations of targeted therapy for aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:38
session highlights: transforming aml treatment and building on new approaches
-
1:42
novel treatment combinations in aml: what’s to come?
-
2:00
associated toxicities of novel therapies for cll